Cargando…

COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review

Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Nas, Kemal, Eryilmaz, Nuran, Geyik, Mehmet Faruk, Altaş, Ayfer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897416/
https://www.ncbi.nlm.nih.gov/pubmed/33611657
http://dx.doi.org/10.1007/s00296-021-04809-3
_version_ 1783653665533329408
author Nas, Kemal
Eryilmaz, Nuran
Geyik, Mehmet Faruk
Altaş, Ayfer
author_facet Nas, Kemal
Eryilmaz, Nuran
Geyik, Mehmet Faruk
Altaş, Ayfer
author_sort Nas, Kemal
collection PubMed
description Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to state that both COVID-19 and inflammatory rheumatic disorders cause a cytokine storm and merit treatment with anti-rheumatic drugs. Three patients, who were on regular follow-up due to the diagnosis of familial Mediterranean fever (FMF), contracted COVID-19 infection; and their pre-clinical and post-clinical data as well as laboratory, prognosis and treatment data were investigated. Effects of colchicine in FMF patients who contracted COVID-19 infection were presented in this study. All the cases recovered from COVID-19 without complications. The present study suggests that colchicine can positively affect the prognosis of COVID-19 in FMF patients; therefore, experience of rheumatologists in the use of anti-inflammatory drugs can be highly instrumental in management of COVID-19 patients.
format Online
Article
Text
id pubmed-7897416
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78974162021-02-22 COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review Nas, Kemal Eryilmaz, Nuran Geyik, Mehmet Faruk Altaş, Ayfer Rheumatol Int Case Based Review Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to state that both COVID-19 and inflammatory rheumatic disorders cause a cytokine storm and merit treatment with anti-rheumatic drugs. Three patients, who were on regular follow-up due to the diagnosis of familial Mediterranean fever (FMF), contracted COVID-19 infection; and their pre-clinical and post-clinical data as well as laboratory, prognosis and treatment data were investigated. Effects of colchicine in FMF patients who contracted COVID-19 infection were presented in this study. All the cases recovered from COVID-19 without complications. The present study suggests that colchicine can positively affect the prognosis of COVID-19 in FMF patients; therefore, experience of rheumatologists in the use of anti-inflammatory drugs can be highly instrumental in management of COVID-19 patients. Springer Berlin Heidelberg 2021-02-21 2021 /pmc/articles/PMC7897416/ /pubmed/33611657 http://dx.doi.org/10.1007/s00296-021-04809-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Based Review
Nas, Kemal
Eryilmaz, Nuran
Geyik, Mehmet Faruk
Altaş, Ayfer
COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
title COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
title_full COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
title_fullStr COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
title_full_unstemmed COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
title_short COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
title_sort covid-19 in patients with familial mediterranean fever treated with colchicine: case based review
topic Case Based Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897416/
https://www.ncbi.nlm.nih.gov/pubmed/33611657
http://dx.doi.org/10.1007/s00296-021-04809-3
work_keys_str_mv AT naskemal covid19inpatientswithfamilialmediterraneanfevertreatedwithcolchicinecasebasedreview
AT eryilmaznuran covid19inpatientswithfamilialmediterraneanfevertreatedwithcolchicinecasebasedreview
AT geyikmehmetfaruk covid19inpatientswithfamilialmediterraneanfevertreatedwithcolchicinecasebasedreview
AT altasayfer covid19inpatientswithfamilialmediterraneanfevertreatedwithcolchicinecasebasedreview